Drug Search Results
More Filters [+]

Tyloxapol

Alternative Names: tyloxapol, exosurf neonatal
Latest Update: 2019-07-31
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: LPL Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Ireland | New Zealand | Taiwan | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Samumed Pacific Pty Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tyloxapol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Respiratory Distress Syndrome, Newborn|Obstetric Labor, Premature|Acute Respiratory Distress Syndrome|Bronchopulmonary Dysplasia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Surfactant 1

P3

Completed

Acute Respiratory Distress Syndrome|Bronchopulmonary Dysplasia|Obstetric Labor, Premature|Respiratory Distress Syndrome, Newborn

1992-01-01

Recent News Events

Date

Type

Title